HUTCHMED (China) Limited (HCM)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Other Ventures	262.97M	266.84M	309.38M	262.57M	236.52M
Other Ventures Growth	-1.45%	-13.75%	17.83%	11.01%	19.60%
Oncology/Immunology - Marketed Products	214.36M	271.53M	164.17M	124.64M	-
Oncology/Immunology - Marketed Products Growth	-21.06%	65.40%	31.71%	-	-
Oncology/Immunology - R&D	71.18M	91.83M	364.45M	39.20M	-
Oncology/Immunology - R&D Growth	-22.48%	-74.80%	829.67%	-	-
Oncology/Immunology - R&D - PRC	-	-	-	-	43.18M
Oncology/Immunology - R&D - PRC Growth	-	-	-	-	320.79%
Oncology/Immunology - Marketed Products - PRC	-	-	-	-	76.43M
Oncology/Immunology - Marketed Products - PRC Growth	-	-	-	-	283.05%
Total	548.51M	630.20M	838.00M	426.41M	356.13M
Total Growth	-12.96%	-24.80%	96.52%	19.73%	56.21%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
People's Republic of China (PRC)	407.45M	452.41M	484.90M	426.41M	-
People's Republic of China (PRC) Growth	-9.94%	-6.70%	13.72%	-	-
U.S. and Others	141.06M	177.79M	353.10M	-	-
U.S. and Others Growth	-20.66%	-49.65%	-	-	-
Total	548.51M	630.20M	838.00M	426.41M	-
Total Growth	-12.96%	-24.80%	96.52%	-	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 7, 2026

Data Sources Report a data error